Skip to Main Content

Author Details

Martin Sj??str??m
University of California-San Francisco
2013
44
15
PMIDPaper TitleJournal TitlePublished Year
37474400Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes.Eur Urol Oncol2024
36599119Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer.J Clin Oncol2023
37961351ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers.bioRxiv2023
37289025The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.Cancer Res2023
37179239Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer.Eur Urol2023
37279434Reply to V. Nardone et al.J Clin Oncol2023
37208129Combining histological grade, TILs, and the PD-1/PD-L1 pathway to identify immunogenic tumors and de-escalate radiotherapy in early breast cancer: a secondary analysis of a randomized clinical trial.J Immunother Cancer2023
37071498Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial.Clin Cancer Res2023
37331779Machine Learning & Molecular Radiation Tumor Biomarkers.Semin Radiat Oncol2023
37031196Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning.Nat Commun2023
37330052Fragmentomic analysis of circulating tumor DNA-targeted cancer panels.Ann Oncol2023
36732562Proteogenomics decodes the evolution of human ipsilateral breast cancer.Commun Biol2023
34792282Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity.Mol Oncol2022
35509021Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.Clin Epigenetics2022
36561929IL-1β expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasis.Cancer Res Commun2022
36260524Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2022
36253482Identification of phenocopies improves prediction of targeted therapy response over DNA mutations alone.NPJ Genom Med2022
36251389The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.Cancer Res2022
35216942TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.Eur Urol Oncol2022
35140341Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up.Br J Cancer2022
33148672Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial.Clin Cancer Res2021
33840559Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.Eur Urol2021
33855848Proteogenomic Workflow Reveals Molecular Phenotypes Related to Breast Cancer Mammographic Appearance.J Proteome Res2021
34554200Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.JAMA Oncol2021
34548481Predicting cancer drug TARGETS - TreAtment Response Generalized Elastic-neT Signatures.NPJ Genom Med2021
34108177Heterogeneity in <i>NECTIN4</i> Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.Clin Cancer Res2021
34326322An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer.Nat Commun2021
31558478Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy.Clin Cancer Res2020
32946618Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast-conserving surgery: a long-term follow-up of the SweBCG91-RT randomised trial.Mol Oncol2020
32302351Plasma membrane expression of G protein-coupled estrogen receptor (GPER)/G protein-coupled receptor 30 (GPR30) is associated with worse outcome in metachronous contralateral breast cancer.PLoS One2020
30321406The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.J Natl Cancer Inst2019
31618132Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer.J Clin Oncol2019
30796653The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.Breast Cancer Res Treat2019
30939091Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial.J Clin Oncol2019
29973242Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors.Breast Cancer Res2018
28759347Response to Radiotherapy After Breast-Conserving Surgery in Different Breast Cancer Subtypes in the Swedish Breast Cancer Group 91 Radiotherapy Randomized Clinical Trial.J Clin Oncol2017
28899973TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup.Clin Cancer Res2017
27121749Cancer associated proteins in blood plasma: Determining normal variation.Proteomics2016
25944384A Combined Shotgun and Targeted Mass Spectrometry Strategy for Breast Cancer Biomarker Discovery.J Proteome Res2015
26439695Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing.Oncotarget2015
26175266Stem cell biomarker ALDH1A1 in breast cancer shows an association with prognosis and clinicopathological variables that is highly cut-off dependent.J Clin Pathol2015
25991917Changes in glycoprotein expression between primary breast tumour and synchronous lymph node metastases or asynchronous distant metastases.Clin Proteomics2015
24715381Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.Breast Cancer Res Treat2014
23554355G protein-coupled estrogen receptor is apoptotic and correlates with increased distant disease-free survival of estrogen receptor-positive breast cancer patients.Clin Cancer Res2013
  • 1 - 44 of 44

Recommended Authors

Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 8
Kevin Punie
Leuven Cancer Institute and University Hospitals Leuven
Career Start Year 2015
Number of shared co-authors 1
Leen Slaets
50148Janssen Pharmaceutica NV
Career Start Year 2014
Number of shared co-authors 0
Konstantinos Tryfonidis
Merck & Co., Inc.
Career Start Year 2011
Number of shared co-authors 0
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 0
Carmen Criscitiello
University of Milano
Career Start Year 2008
Number of shared co-authors 0
Melanie Spears
Ontario Institute for Cancer Research
Career Start Year 2008
Number of shared co-authors 1
Samuel Leung
University of British Columbia
Career Start Year 2007
Number of shared co-authors 1
Catherine M Kelly
Mater Misericordiae University Hospital
Career Start Year 2006
Number of shared co-authors 1
Christina Yau
University of California San Francisco
Career Start Year 2005
Number of shared co-authors 1
Benjamin Haibe-Kains
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 11
Katherine A Hoadley
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Career Start Year 2004
Number of shared co-authors 7
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 4
Joshua Chuck Harrell
Virginia Commonwealth University
Career Start Year 2002
Number of shared co-authors 0
Philippe L Bedard
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2002
Number of shared co-authors 4
Britta Weigelt
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 4
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Career Start Year 2002
Number of shared co-authors 4
Nicola Fusco
IEO European Institute of Oncology IRCCS
Career Start Year 2002
Number of shared co-authors 2
Richard B Schwab
Department of Medicine and Moores Cancer Center, University of California San Diego
Career Start Year 2000
Number of shared co-authors 0
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 14
Massimo Cristofanilli
Weill Cornell School of Medicine
Career Start Year 1998
Number of shared co-authors 1
Ingrid Hedenfalk
Lund University and Skane University Hospital
Career Start Year 1997
Number of shared co-authors 4
Giuseppe Curigliano
University of Milan
Career Start Year 1996
Number of shared co-authors 2
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 0
Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Career Start Year 1995
Number of shared co-authors 1
John M S Bartlett
University of Edinburgh
Career Start Year 1992
Number of shared co-authors 3
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Career Start Year 1992
Number of shared co-authors 5
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Career Start Year 1990
Number of shared co-authors 3
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Career Start Year 1989
Number of shared co-authors 9
Laura J Van't Veer
University of California San Francisco
Career Start Year 1984
Number of shared co-authors 6

Collaborators

Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 22
David A Quigley
University of California-San Francisco
Co-authored papers 9
Eric J Small
University of California san francisco
Co-authored papers 7
Joshua M Lang
19University of Wisconsin Carbone Cancer Center.
Co-authored papers 6
Jonathan Chou
University of California san francisco
Co-authored papers 6
Elai Davicioni
Veracyte Inc.
Co-authored papers 6
Rahul Aggarwal
University of California San Francisco
Co-authored papers 5
Raunak Shrestha
University of California San Francisco
Co-authored papers 4
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 3
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Co-authored papers 3
Adam Foye
University of California San Francisco
Co-authored papers 3
Christopher P Evans
University of California Davis
Co-authored papers 3
Edward M Schaeffer
Northwestern University Feinberg School of Medicine
Co-authored papers 3
Robert Jeffrey Karnes
Mayo Clinic
Co-authored papers 3
Ashley E Ross
Northwestern University
Co-authored papers 3
Alexander W Wyatt
University of British Columbia
Co-authored papers 3
Mohammed Alshalalfa
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Co-authored papers 3
Martin E Gleave
University of British Columbia
Co-authored papers 3
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 3
Fei-Fei Liu
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Co-authored papers 2
Owen N Witte
University of California los angeles
Co-authored papers 2
Lisa N Chesner
University of California san francisco
Co-authored papers 2
Tomasz M Beer
OHSU Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 2
David R McCready
University of Toronto, University Health Network
Co-authored papers 2
Kim N Chi
University of British Columbia
Co-authored papers 2
Housheng Hansen He
Princess Margaret Cancer Center, University Health Network, University of Toronto
Co-authored papers 2
Junjie T Hua
School of Public Health, Sun Yat-sen University
Co-authored papers 2
Luke A Gilbert
Arc Institute
Co-authored papers 2
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 2
Lawrence Fong
University of California san francisco
Co-authored papers 2
Release 1.2